|
Match
|
Document |
Document Title |
|
|
US20080113011 |
Compositions and methods for enhanced mucosal delivery of interferon beta
Compositions and methods are provided for intranasal delivery of interferon-β yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon-β...
|
|
|
US20080107627 |
USE OF SARP-1 FOR THE TREATMENT AND/OR PREVENTION OF SCLERODERMA
The invention relates to the use of SARP-1 for the preparation of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis.
|
|
|
US20080089861 |
Combination therapy for treatment of demyelinating conditions
The invention provides compositions and methods for treating autoimmune diseases such as multiple sclerosis. The compositions include a combination of an NMDA Receptor antagonist, such as memantine...
|
|
|
US20080089860 |
Therapeutic compositions and methods useful in treating cancer
The invention encompasses therapeutic compositions containing a pentavalent antimonial composition. The pentavalent antimonial can be sodium stibogluconate and pentamidine and biological...
|
|
|
US20080075697 |
METHODS FOR TREATING MULTIPLE SCLEROSIS
Methods for treating multiple sclerosis (MS) and clinically isolated syndromes suggestive of MS are provided. The methods comprise administering a therapeutically effective dose of interferon-beta...
|
|
|
US20080075696 |
Treatment Of Hepatitis C In The Asian Population With Interferon-Beta
The invention relates to the use of IFN-beta in the manufacture of a medicament for the treatment of an HCV infection in a treatment-naïve patient belonging to the Asian population.
|
|
|
US20080075695 |
COMBINATION THERAPY METHOD FOR TREATING HEPATITIS C VIRUS INFECTION AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN
Combination therapy methods for the treatment of hepatitis C virus infection and associated diseases, by the co-administration of...
|
|
|
US20080050340 |
CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or...
|
|
|
US20080038224 |
Modified interferon-beta (IFN-beta) polypeptides
Provided are modified interferon-beta polypeptides and nucleic acid molecules encoding modified interferon-beta polypeptides and formulations containing the polypeptides and/or nucleic acid...
|
|
|
US20080031852 |
PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS
|
|
|
US20080008682 |
Modulators of toll-like receptor 7
The present application provides for a compound of Formula I or II:
or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic...
|
|
|
US20080008681 |
MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:
which inhibit serine protease activity,...
|
|
|
US20080003202 |
Modified interferon-beta (IFN-beta) polypeptides
Provided are modified interferon-beta polypeptides and nucleic acid molecules encoding modified interferon-beta polypeptides and formulations containing the polypeptides and/or nucleic acid...
|
|
|
US20080003200 |
GRP78 targeting peptides and methods employing same
The compositions and methods include targeting peptides selective for tissue selective binding, particularly prostate and/or bone cancer, or adipose tissue. The methods may comprise targeting...
|